Want to see CYRX full AI Analyst Report?
CYRX Stock Chart & Stats
$9.21
$0.06(0.70%)
At close: 4:00 PM EST
$9.21
$0.06(0.70%)
Day’s Range― - ―
52-Week Range$6.69 - $16.73
Previous CloseN/A
Volume42.91K
Average Volume (3M)690.07K
Market Cap
$780.73M
Enterprise Value$691.94M
Total Cash (Recent Filing)$403.63M
Total Debt (Recent Filing)$230.49M
Price to Earnings (P/E)10.8
Beta1.31
Next Earnings
Aug 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.43
Shares Outstanding50,402,313
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.78
Enterprise Value/Gross Profit8.02
Enterprise Value/Ebitda-109.62
Forecast
1Y Price Target
$14.83Price Target Upside61.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$194.40M
Bulls Say, Bears Say
Bulls Say
Large Clinical PipelineA deep and growing clinical trial base (766 trials, 91 Phase III) provides a durable, high-value addressable market and recurring shipment demand. As trials mature to later phases and commercialize, Cryoport benefits from sticky, higher-margin commercial conversions that support multi-quarter revenue visibility.
Product Innovation Expanding Addressable MarketNew product introductions (e.g., Fusion 800) and strong demand for proprietary MVE systems demonstrate sustainable product-led growth. Proprietary packaging and systems create differentiation, recurring consumable demand, and higher switching costs that can preserve product margins and expand long-term market share.
Improved Balance Sheet And Healthy Gross MarginsHealthy gross margins (~47%) and a manageable leverage profile (debt/equity ~0.46) provide structural capacity to fund growth investments and facility ramps. Improved balance-sheet metrics versus prior years reduce refinancing risk and support sustained investment in capacity and product development over the next several quarters.
Bears Say
Weak Cash GenerationMaterially negative free cash flow and still-negative operating cash flow indicate earnings are not being converted into durable cash, constraining self-funding of expansion and increasing reliance on external capital. Over 2–6 months this limits flexibility to scale facilities and may pressure capital allocation choices.
Core Operating Profitability Not Yet AchievedAdjusted EBITDA near breakeven but still negative signals the business has yet to consistently deliver operating profits from core services. Reliance on non-operational items to support net income risks earnings quality and makes sustainable margin expansion contingent on execution across multiple quarters.
Long Ramp And Execution Risk For New InitiativesMulti-quarter onboarding and facility ramp timelines (12–18 months for IntegraCell; limited 2026 facility contribution) delay material revenue and margin benefits. This creates execution risk: investments tied up for extended periods before payoff, making near-term profitability sensitive to onboarding pace and customer conversion rates.
CryoPort News
CYRX FAQ
What was CryoPort Inc’s price range in the past 12 months?
CryoPort Inc lowest stock price was $6.69 and its highest was $16.73 in the past 12 months.
What is CryoPort Inc’s market cap?
CryoPort Inc’s market cap is $780.73M.
When is CryoPort Inc’s upcoming earnings report date?
CryoPort Inc’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.
How were CryoPort Inc’s earnings last quarter?
CryoPort Inc released its earnings results on May 04, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.216 by -$0.034.
Is CryoPort Inc overvalued?
According to Wall Street analysts CryoPort Inc’s price is currently Undervalued.
Does CryoPort Inc pay dividends?
CryoPort Inc does not currently pay dividends.
What is CryoPort Inc’s EPS estimate?
CryoPort Inc’s EPS estimate is -0.19.
How many shares outstanding does CryoPort Inc have?
CryoPort Inc has 50,402,313 shares outstanding.
What happened to CryoPort Inc’s price movement after its last earnings report?
CryoPort Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.216. Following the earnings report the stock price went up 19.393%.
Which hedge fund is a major shareholder of CryoPort Inc?
Currently, no hedge funds are holding shares in CYRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CryoPort Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.83 (61.06% Upside)
$14.83 (61.06% Upside)
Hedge Fund Trend
Increased
By 432.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.93%
12-Months-Change
Fundamentals
Return on Equity
16.16%
Trailing 12-Months
Asset Growth
9.11%
Trailing 12-Months
Company Description
CryoPort Inc
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
CYRX Company Deck
CYRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong 16% revenue growth, double-digit expansion across services and products, record clinical trial support, product innovation (Fusion 800), and a $2.2M improvement in adjusted EBITDA. Management raised full-year revenue guidance and expects positive adjusted EBITDA in H2 2026. Key near-term cautions include a conservative guide raise despite a beat, the company not yet at positive adjusted EBITDA, product-margin mix variability, and multi-quarter ramps for IntegraCell and new facilities that limit 2026 contribution. Overall the positives (top-line growth, pipeline depth, milestones, margin improvement initiatives, and operational expansions) materially outweigh the identified lowlights.View all CYRX earnings summariesCYRX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$14.83
▲(61.06% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
3.61% Insiders
17.58% Mutual Funds
37.64% Other Institutional Investors
27.39% Public Companies and
Individual Investors







